Marks Group Wealth Management »

Cytokinetics shares owned by Marks Group Wealth Management

Quarter-by-quarter ownership of Cytokinetics (CYTK) shares owned by Marks Group Wealth Management from 13F filings

Historical chart of Marks Group Wealth Management investment in Cytokinetics

Tip: Access up to 7 years of quarterly data

All positions including Cytokinetics held by Marks Group Wealth Management consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Cytokinetics by Marks Group Wealth Management

Quarter filed Position value Share count Share price at filing
2025-12-31 $926k 15k 63.54

More positions owned by Marks Group Wealth Management

Alphabet Cap Stk Cl C (GOOG)
Apple (AAPL)
Ishares Tr Eafe Value Etf (EFV)
Microsoft Corporation (MSFT)
NVIDIA Corporation (NVDA)
Republic Services (RSG)
Meta Platforms Cl A (META)
UnitedHealth (UNH)
Intercontinental Exchange (ICE)
Stryker Corporation (SYK)
Ishares Core Msci Emkt (IEMG)
Ge Aerospace Com New (GE)
salesforce (CRM)
Amazon (AMZN)
Visa Com Cl A (V)

View all positions for Marks Group Wealth Management

Top funds holding Cytokinetics

T. Rowe Price Investment Management
BlackRock
FMR
Vanguard Group
Wellington Management Company
State Street Corporation
Deep Track Capital
Geode Capital Management
Susquehanna International
Rtw Investments
Goldman Sachs Group
Polar Capital Holdings
Armistice Capital
Integral Health Asset Management
Citadel Advisors

View all funds holding Cytokinetics